A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy

Brian D. Ross(University of Michigan), Marcian E. Van Dort(University of Michigan)

Nature Communications

August 17, 2022

10.1038/s41467-022-32486-8

Cited by 14

Related Papers

Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy

|Clinical Cancer Research|2007|88

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model

|Neoplasia|2016|27